Us Adalimumab Market Size By Applications, By Type, By End-User, By Deployment & By Technology 2032
Adalimumab Market was valued at USD 20.5 Billion in 2022 and is projected to reach USD 37.1 Billion by 2030, growing at a CAGR of 8.2% from 2024 to 2030.
The U.S. adalimumab market has undergone significant transformations, especially with the introduction of biosimilars. Adalimumab, originally marketed as Humira by AbbVie, is a monoclonal antibody used to treat various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease. Humira has been a cornerstone in autoimmune disease management, generating substantial revenue for AbbVie. However, the expiration of Humira's patent in July 2023 opened the door for biosimilars to enter the U.S. market, aiming to provide more affordable treatment options. The initial uptake of these biosimilars was modest, with combined market share representing just 2% by the end of 2023. This slow adoption was influenced by factors such as physician familiarity, patient trust, and insurance formulary decisions. However, by mid-2024, the landscape began to shift. Reports indicated that biosimilars had captured approximately 18% of the market, with Sandoz's Hyrimoz leading the charge, accounting for around 13% of the market share. This surge was partly due to strategic collaborations, such as the partnership between Sandoz and CVS Health's Cordavis, which facilitated broader access to biosimilars. The competitive pricing strategies of biosimilars have also played a crucial role in their adoption. For instance, Evernorth Health Services announced that a biosimilar of Humira would be available at no out-of-pocket cost for eligible patients through its specialty pharmacy, Accredo. This initiative aimed to make treatment more accessible and affordable for patients. Despite these advancements, challenges remain. Pharmacy Benefit Managers (PBMs) have faced scrutiny over practices that may suppress the uptake of biosimilars, potentially hindering the transition from branded to biosimilar adalimumab. The market dynamics continue to evolve, with ongoing efforts to balance cost, accessibility, and patient outcomes. The introduction of biosimilars has disrupted the U.S. adalimumab market, offering patients more treatment options and potentially reducing healthcare costs. As the market continues to mature, it will be essential to monitor how these changes impact patient care and the broader healthcare landscape. The evolution of the adalimumab market underscores the importance of innovation and competition in improving healthcare accessibility and affordability.
Get an In-Depth Research Analysis of the Global Adalimumab Market Size And Forecast [2025-2032]
AbbVie
Amgen
Sandoz
Boehringer Ingelheim
Mylan
Biogen
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global Adalimumab Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Global Adalimumab Market
Rheumatoid Arthritis
Psoriatic Arthritis
Crohn's Disease
Ulcerative Colitis
Hidradenitis Suppurativa
Ankylosing Spondylitis
Psoriasis
Subcutaneous Injection
Intravenous Infusion
Combination Delivery Systems
Pediatric Patients
Adult Patients
Geriatric Patients
First-Line Treatment
Second-Line Treatment
Third-Line and Beyond
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Clinics
Direct-to-Consumer Sales
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Adalimumab Market Research Analysis
1. Introduction of the Global Adalimumab Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global Adalimumab Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global Adalimumab Market, By Type
6. Global Adalimumab Market, By Application
7. Global Adalimumab Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global Adalimumab Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/